Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Significantly expands its capabilities for in vitro and in vivo studies.
November 10, 2020
By: Contract Pharma
Contract Pharma Staff
MercachemSyncom, a leading mid-sized European drug-discovery contract research organization, has acquired Admescope Ltd. based in Oulu, Finland and Södertälje, Sweden. The acquisition will give MercachemSyncom significantly expanded capabilities for tailor-made in vitro and in vivo ADME-Tox studies for pre-clinical and early clinical R&D projects and seamless integration with the existing medicinal, synthetic and development chemistry capabilities of MercachemSyncom. Admescope brings expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis. Financial terms were not disclosed. Admescope has seen significant growth in subsequent years and currently employs 40 highly qualified and experienced scientists. The scientific and management teams have consolidated experience in tailored ADME-Tox studies for pharma and biotech clients all over the world. Studies are carried out at research laboratories in both Oulu and Södertälje, Sweden with emphasis on a deep understanding of customers’ needs, in-house processes and how to design the most effective studies to satisfy them. ‘A Perfect Match’ Eelco Ebbers, CEO of MercachemSyncom, says he is happy to welcome Admescope to MercachemSyncom. “MercachemSyncom is at the forefront of a continuing consolidation of high-quality contract research and manufacturing organizations into medium-sized, but still agile, companies able to offer an extended palette of R&D services to long-standing and new clients,” he remarked. Ebbers continued, “I am convinced that the addition of Admescope, a world-class company offering high quality, innovative and client-centric ADME-Tox services to our organization is a perfect match, both in terms of complementarity and working philosophy… This approach fits perfectly with MercachemSyncom’s approach to discovery and development.” Ari Tolonen, CEO of Admescope, added, “We are thrilled to continue our successful growth as a part of MercachemSyncom. We feel that the cultural fit between our companies is excellent, and with the support of MercachemSyncom we will be able to continue meeting and exceeding our customers’ expectations for contract research services.” “MercachemSyncom’s global presence greatly increases our exposure to new companies that we can help with our ADME-Tox services. While Admescope’s focus will remain in providing our existing and new customers with the top-quality services and customer experience that they are used to, together with MercachemSyncom we can offer a wider spectrum of services to cover the needs of our customers, as well as further expand our service offering,” Tolonen concluded.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !